<SEC-DOCUMENT>0001193125-25-286188.txt : 20251118
<SEC-HEADER>0001193125-25-286188.hdr.sgml : 20251118
<ACCEPTANCE-DATETIME>20251118161929
ACCESSION NUMBER:		0001193125-25-286188
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251118
DATE AS OF CHANGE:		20251118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		251494955

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d25862d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,770,000 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>885,000,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g25862g1118222709495.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on November&nbsp;18, 2025 (the &#8220;November 18, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#8221;).</FONT> Accordingly, we have
attached the November&nbsp;18, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;KZIA.&#8221; On November&nbsp;17, 2025, the last reported sale
price of the ADSs on Nasdaq was $6.08 per ADS. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page 9 of the Prospectus and the &#8220;Risk
Factors&#8221; in &#8220;Item 3. Key <FONT STYLE="white-space:nowrap">Information-D.</FONT> Risk Factors&#8221; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the
Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is November&nbsp;18, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, Kazia Therapeutics Limited (the &#8220;Company&#8221;) received a notice (the &#8220;Notice&#8221;) from the
Listing Qualifications department (the &#8220;Staff&#8221;) of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on May&nbsp;12, 2025 notifying the Company that from March&nbsp;28, 2025 to May&nbsp;9, 2025, the Company&#8217;s Market Value of
Listed Securities (&#8220;MVLS&#8221;) was below the minimum of $35&nbsp;million required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the &#8220;MVLS Requirement&#8221;). In accordance with Nasdaq
Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until November&nbsp;10, 2025 (the &#8220;Compliance Date&#8221;), to regain compliance with the MVLS Requirement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;12, 2025, the Company received a staff determination letter (&#8220;Staff Letter&#8221;) from the Staff of Nasdaq indicating
that the Company had not regained compliance with the MVLS Requirement by November&nbsp;10, 2025. Pursuant to the Nasdaq Listing Rules and the Staff Letter, unless the Company timely requests a hearing before a Hearings Panel (the
&#8220;Panel&#8221;), the Company&#8217;s securities would be subject to suspension/delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting
action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the
hearing, the Company intends to demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term compliance with all applicable maintenance criteria. There can be no assurance that
the Company&#8217;s plan to regain compliance presented at the hearing will be accepted by the Panel, or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein into the Company&#8217;s registration statement on Form <FONT
STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-281937).</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report of foreign private issuer on Form <FONT STYLE="white-space:nowrap">6-K</FONT> may contain forward-looking statements, which can
generally be identified as such by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;future,&#8221; &#8220;forward,&#8221; &#8220;anticipate,&#8221; or other similar words. Any statement describing
Kazia&#8217;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding:
Kazia&#8217;s intent to demonstrate its ability to regain compliance with the MVLS requirement, the outcome of the Panet&#8217;s review of any Kazia appeal of the Staff&#8217;s determination, and any course of action to regain compliance with the
Nasdaq continued listing requirements. Such statements are based on Kazia&#8217;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with Kazia&#8217;s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing
requirements and standards. These and other risks and uncertainties are described more fully in Kazia&#8217;s Annual Report, filed on <FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;with</FONT> the SEC on November&nbsp;7, 2025, and in
subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required
under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this report of foreign private issuer on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;18, 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g25862g1118222709495.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g25862g1118222709495.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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&BDHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
